207 related articles for article (PubMed ID: 17567542)
1. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
Van Laethem K; Pannecouque C; Vandamme AM
Infect Genet Evol; 2007 Sep; 7(5):600-3. PubMed ID: 17567542
[TBL] [Abstract][Full Text] [Related]
2. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
4. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
Brenner BG; Oliveira M; Doualla-Bell F; Moisi DD; Ntemgwa M; Frankel F; Essex M; Wainberg MA
AIDS; 2006 Jun; 20(9):F9-13. PubMed ID: 16816549
[TBL] [Abstract][Full Text] [Related]
6. Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Bradshaw D; Malik S; Booth C; Van Houtte M; Pattery T; Waters A; Ainsworth J; Geretti AM
Antimicrob Agents Chemother; 2007 Dec; 51(12):4489-91. PubMed ID: 17876005
[TBL] [Abstract][Full Text] [Related]
7. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
[TBL] [Abstract][Full Text] [Related]
8. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V
Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370
[TBL] [Abstract][Full Text] [Related]
9. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ
J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419
[TBL] [Abstract][Full Text] [Related]
10. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
[TBL] [Abstract][Full Text] [Related]
11. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
[TBL] [Abstract][Full Text] [Related]
12. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
Mouroux M; Descamps D; Izopet J; Yvon A; Delaugerre C; Matheron S; Coutellier A; Valantin MA; Bonmarchand M; Agut H; Massip P; Costagliola D; Katlama C; Brun-Vezinet F; Calvez V
Antivir Ther; 2001 Sep; 6(3):179-83. PubMed ID: 11808752
[TBL] [Abstract][Full Text] [Related]
13. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
15. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
Goldschmidt V; Marquet R
Int J Biochem Cell Biol; 2004 Sep; 36(9):1687-705. PubMed ID: 15183338
[TBL] [Abstract][Full Text] [Related]
16. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
[TBL] [Abstract][Full Text] [Related]
17. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
18. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors.
Fitzgibbon JE; DiCola B; Arnold E; Das K; Sha BE; Pottage JC; Nahass R; Gaur S; John JF
Antivir Ther; 2001 Dec; 6(4):231-8. PubMed ID: 11878404
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
Rezende LF; Prasad VR
Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
